Clinical Research
South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.
Medical Staff
Deborah Lund, RN
Wendy Doroski, ANP-C
Kaitlyn Jaenicke
Olivia Kaczmarek
Enrolling Studies as of 08/19/2020
Study Name |
Coordinator |
Extension |
Disease |
Study Description |
| Argenx ADHERE ARGX-113-1802/1902 |
Deborah/Kaitlyn | 2205/2246 | CIDP | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE) |
| ENLIGHTEN RPC-1063-MS-001 |
Deborah/Kaitlyn | 2205/2246 | MS | A Multicenter, Longitudinal, Open-Label, Single-arm study describing cognitive processing speed changes in relapsing multiple sclerosis subject treated with ozanimod (RPC-1063). |
| EVOLUTION MS200527_0080 | Deborah/Kaitlyn | 2205/2246 | MS | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. |
| GEMINI 2 EFC16034 |
Deborah/Kaitlyn | 2205/2246 | MS | A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis. |
| OCEAN 231MS201 | Deborah/Kaitlyn | 2205/2246 | MS | A multicenter, double-blind, placebo-controlled, parallel-group, dose ranging Phase 2 study to evaluate the efficacy and safety of oral BIIB061 as add-on therapy to interferon-beta 1 or Glatiramer Acetate therapies in relapsing MS. |
| ROPAD |
Wendy/Olivia | 2207/2206 | Parkinson's | Rostock International Parkinson’s Disease Study Program: An International, Multicenter, Epidemiological Observational Study All Parkinson’s patients are eligible for free genetic testing. |
| VERISMO BA39731 | Deborah/Kaitlyn | 2205/2246 | MS | An Observational study of Ocrelizumab-treated patients with multiple sclerosis to determine the incidence and mortality rates of breast cancer and all malignancies. |
Locations where this service is offered:
Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772
Tel: 631-758-1910
Fax: 631-750-1014